Nykode Therapeutics Denmark A/S: Financial statements 2021
CVR: 42038660
Source: annual report 2021, Danish Business Authority
08/01/2021 – 31/12/2021
Nykode Therapeutics Denmark A/S (CVR 42038660) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 10,590,585 and a net result of DKK 578,082. Equity in the 2021 report amounted to DKK 978,082. The solvency ratio was 8.9%. The company had 7 employees in the financial year.
- Gross Profit
- DKK 10,590,585
- Profit/Loss
- DKK 578,082
- Equity
- DKK 978,082
- Total Assets
- DKK 10,953,602
- Employees
- 7
Official annual report
Find more companies like Nykode Therapeutics Denmark A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
On December 20, 2021, the company changed its name from Vaccibody Denmark A/S to Nykode Therapeutics Denmark A/S.
As of April 21, 2021, Katrine Hovgaard Husum has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of April 21, 2021, Lars Dencker Nielsen has left the board of directors of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, Lars Dencker Nielsen has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, Michael Thyrring Engsig has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, Anders Tuv has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, Michael Thyrring Engsig is registered as director of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, is registered as an owner of Nykode Therapeutics Denmark A/S with an ownership share of 100%.
Nykode Therapeutics Denmark A/S was founded on January 8, 2021.
About Nykode Therapeutics Denmark A/S
Nykode Therapeutics Denmark A/S is a Danish company of the type Aktieselskab based in Kongens Lyngby, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named Vaccibody Denmark A/S. The management consists of Michael Thyrring Engsig. The board consists of Louise Stubbe (chair), Harald Gurvin and Michael Thyrring Engsig. The company is owned by Nykode Therapeutics ASA. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 31,839,001 and a net result of DKK 1,347,127 compared with DKK 156,959 the year before. Equity in the 2025 report amounted to DKK 6,862,099.
